Protalix BioTherapeutics announced that the company’s management and Board of Directors have decided that it is in the best interest of the company to voluntarily delist its common stock from the Tel Aviv Stock Exchange. The company believes that delisting its common stock from the TASE will allow management to focus better on the company’s primary capital market and reduce its cost of operations as the company will be subject to only one set of listing rules and regulations. Accordingly, the company has requested that the TASE immediately initiate the delisting process.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PLX:
- Biotech Alert: Searches spiking for these stocks today
- Protalix to hold a KOL webcast
- Protalix, Chiesi Global Rare Diseases announce FDA acceptance of PRX-102 BLA
- Protalix BioTherapeutics Reports Third Quarter 2022 Financial and Business Results
- Protalix, Chiesi Global Rare Diseases resubmits PRX-102 BLA to FDA
